[Role of etiol (amifostine) in the treatment of patients with malignant lymphoma].
The material is devoted to using of amifostinum as cytoprotor during polychemotherapy application in patients with malignant lymphomas. 10 patients (5 with lymphogranulomatosis, 4 with non-Hodgkin's lymphoma and 1 with Ewing's sarcoma) were receiving along with cytostatic therapy amifostinum. The patients treated with combined therapy had less side effects of polychemotherapy than a control group which had been receiving only polychemotherapy. The number of lymphocytes was constant in the group using amifostinum in contrast to another group where decrease of lymphocytes by 24% was noted. Owing to amifostinum we could complete the course of treatment even in patients whose state didn't allow us of sufficiently using polychemotherapy.